Armored immune cells take on deadly brain tumor in first human test
NCT ID NCT07172178
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This early-phase study tests a new treatment for malignant meningioma, a rare and aggressive brain tumor. Researchers combine special immune cells (γδ T cells) with a PD-1 antibody to help them attack the tumor. The study will enroll 12 adults whose tumor has returned, to check if the treatment is safe and to look for early signs of effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.